The Effect of Fish Oil in Major Depressive Disorder

National Science Council, Taiwan

Status

Completed

Conditions

Major Depressive Disorder

Treatments

Dietary Supplement: Placebo

Dietary Supplement: Omega-3 fatty acids

Study type

Interventional

Funder types

Other

Identifiers

NCT00816322

DMR93-IRB-87

Details and patient eligibility

About

The whole study was divided into two major parts: (A) the 12-week, double-blind, randomized controlled, parallel omega-3 fatty acid monotherapy study in 60 patients with mild to moderate major depressive disorder. (B) The double-blind, randomized controlled, parallel omega-3 fatty acid add-on prevention study in 60 patients with major depressive disorder in recovery status.

The goals of this study were to examine the therapeutic and recurrence prevention effects of omega-3 fatty acids on major depressive disorder.

Enrollment

120 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

DSM-IV criteria for major depressive disorder.
Age being age 18-65.
Capacity and willingness to give written informed consent.

Exclusion criteria

Any major medical illnesses.
A recent or past history of any Axis-I diagnoses besides major depressive disorder, including psychotic disorders; cognitively impaired mental disorders; impulse control disorders; substance use disorder or substance abuse (last 6 months prior to the studies); primary anxiety disorders, including post-traumatic stress disorder and panic disorder; and bipolar disorders; or Axis-II diagnoses, i.e. borderline and antisocial personality disorder.